Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant CRC treatment.

We came across a bullish thesis on Day One Biopharmaceuticals, Inc. (DAWN) on Twitter by Pharmdca. In this article, we will ...

The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.

Researchers at the University of California San Diego have uncovered a key mechanism underlying the treatment resistance of ...

Intraoperative ultra-rapid droplet digital polymerase chain reaction (UR-ddPCR) can identify tumor genetic subtype and ...

Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors, ...

In this video, Arvind N. Dasari, MD, MS, discussed the phase 3 results from the BREAKWATER trial presented at ASCO Gastrointestinal Cancers Symposium.

Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Con ...

Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials ...

When combined with chemotherapy, cetuximab shows promising efficacy for optimizing treatment strategies for patients with metastatic colorectal cancer.

A case study on how one of the leading pharma companies in the oncology space approached DelveInsight with a pressing need for conference coverage to monitor the activities and data readouts of ...